• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Do Men and Women Experience the Same Reduction in Colorectal Cancer Following Sigmoidoscopy?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • The USPSTF recommends screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults (50 to 75 years of age)
    • Based on data between 10-17 years follow-up
    • Effectiveness in women remains uncertain
  • Holme et al. (Annals of Internal Medicine, 2018) examined the long-term effects of flexible sigmoidoscopy screening on colorectal cancer (CRC) incidence and mortality

METHODS:

  • Randomized controlled trial (RCT)
    • Adults aged 55 to 64 years without prior CRC
    • Between 1999 – 2000
  • Patients were randomized to receive either
    • Screening with flexible sigmoidoscopy with and without additional ‘once only’ fecal blood testing
    • No screening
  • Primary outcome
    • Age-adjusted CRC incidence and mortality
  • Secondary outcomes
    • CRC incidence and mortality in women and men | In the distal colon (rectum and sigmoid colon) | Proximal colon

RESULTS:

  • 98,678 people were included in the study
    • 20,552 in screening group | 78,126 in no screening group
    • Adherence rates: 64.7% in women and 61.4% in men
    • Median follow-up was 14.8 years
  • absolute risks for CRC in women – no significant difference
    • 1.86% in the screening group
    • 2.05% in the control group
    • Risk difference: −0.19% (95% CI, −0.49 to 0.11%)
    • Hazard Ratio (HR) 0.92 (95% CI, 0.79 to 1.07)
  • Absolute risks for death from CRC in women – no significant difference
    • 0.60% in the screening group
    • 0.59% in the control group
    • Risk difference, 0.01% (95% CI, −0.16 to 0.18%)
    • HR 1.01 (95% CI, 0.77 to 1.33)
  • Absolute risks for CRC in men – significant difference (P= 0.004)
    • 1.72% in the screening group
    • 2.50% in the control group
    • Risk difference, −0.78 percentage point (95% CI, −1.08 to −0.48%)
    • HR 0.66 (95% CI, 0.57 to 0.78)
  • Absolute risks for death from CRC in men – significant difference (P= 0.014)
    • 0.49% in the screening group
    • 0.81% in the control group
    • Risk difference, −0.33% (95% CI, −0.49 to −0.16%)
    • HR 0.63 (95% CI, 0.47 to 0.83)
  • In the screening group, no difference was seen between the ‘once only’ fetal occult blood testing group and the group without occult blood testing

CONCLUSION:

  • Sigmoidoscopy screening reduced CRC incidence by 34% and reduced related mortality by 37% in men, minimal to no clinical impact in women
  • Reason for minimal difference in women is unclear
  • Authors state that

Colonoscopy may be a better screening method than sigmoidoscopy in women, as suggested by others. However, this is uncertain because randomized trials on the effectiveness of colonoscopy screening are still ongoing

Learn More – Primary Sources:

Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What Percentage of Individuals under 50 Years of Age with Colon Cancer Have Mutations Associated with Heritable Cancer?
Does Warfarin Protect Against Cancer?
Are Heavy Drinkers at Greater Risk for Cancer?
Ovarian or Endometrial Cancer? Consider Lynch Syndrome

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site